IDEAS home Printed from https://ideas.repec.org/p/ern/wpaper/02-2012.html
   My bibliography  Save this paper

I Farmaci Oncologici in Italia: innovazione e sostenibilità economica

Author

Listed:
  • Fabio Pammolli

    () (Politecnico di Milano and CERM Foundation - Competitività, Regole, Mercati)

  • Massimo Riccaboni

    () (IMT Lucca Institute for Advanced Studies and Department of Managerial Economics, Strategy and Innovation, K.U. Leuven)

  • Nicola Carmine Salerno

    () (Ufficio parlamentare di bilancio)

Abstract

I farmaci innovativi ad alto costo ci fanno toccare con mano quali potranno essere i dilemmi della sanità futura se non si completano le riforme della governance di questo capitolo complesso della spesa pubblica (non solo federalismo, ma sistemi contabili e di reporting, schemi di compartecipazione al costo, screening delle prassi terapeutiche per sollecitare best practice, etc.). Quel trade-off crudo che abbiamo di fronte, tra sostenibilità della spesa e domanda di prestazioni da parte dei cittadini, è, per i farmaci ad alto costo, già una realtà vissuta in tutti gli ospedali. Nella prima parte del rapporto Pammolli, Riccaboni e Salerno descrivono le caratteristiche del comparto, fornendone le grandezze principali attuali e prospettiche, anche in chiave di comparazione internazionale. Nella seconda parte, gli autori approfondiscono il quadro normativo-regolatorio che attualmente presiede alla governance dei farmaci oncologici in Italia. Ne emerge un sistema con ombre e approssimazioni, con impostazioni diverse e spesso incompatibili tra Aifa e Regioni, tra Regione e Regione, addirittura tra Als e Ospedali di una stessa Regione. Un assetto poco trasparente e certo non pronto a governare in maniera positiva e programmatica la forbice tra risorse spendibili e necessità e urgenza delle terapie. Nella parte conclusiva del rapporto si avanzano alcune proposte di policy, distinguendo tra quelle attuabili in tempi brevi e quelle per le quali sono necessari tempi di attuazione più lunghi. Le due tipologie di intervento andrebbero avviate il prima possibile e auspicabilmente condotte in parallelo.

Suggested Citation

  • Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2012. "I Farmaci Oncologici in Italia: innovazione e sostenibilità economica," Working Papers CERM 02-2012, Competitività, Regole, Mercati (CERM).
  • Handle: RePEc:ern:wpaper:02-2012
    as

    Download full text from publisher

    File URL: https://fondazionecerm.it/wp-content/uploads/wp/wpcerm-2012-02.pdf
    File Function: First version, 2012
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Sergey V. Buldyrev & Jakub Growiec & Fabio Pammolli & Massimo Riccaboni & H. Eugene Stanley, 2007. "The Growth of Business Firms: Facts and Theory," Journal of the European Economic Association, MIT Press, vol. 5(2-3), pages 574-584, 04-05.
    2. Angus Deaton, 2003. "Health, Inequality, and Economic Development," Journal of Economic Literature, American Economic Association, vol. 41(1), pages 113-158, March.
    3. repec:pri:cheawb:cutler_deaton_lleras-muney_determinants_mortality_nberdec05 is not listed on IDEAS
    4. Dongfeng Fu & Fabio Pammolli & S. V. Buldyrev & Massimo Riccaboni & Kaushik Matia & Kazuko Yamasaki & H. E. Stanley, 2005. "The Growth of Business Firms: Theoretical Framework and Empirical Evidence," Papers physics/0512005, arXiv.org.
    5. Fabio Pammolli & Massimo Riccaboni & Laura Magazzini, 2010. "The productivity crisis in pharmaceutical R&D," Working Papers 06/2010, University of Verona, Department of Economics.
    6. repec:pri:rpdevs:cutler_deaton_lleras-muney_determinants_mortality_nberdec05 is not listed on IDEAS
    7. Davide Integlia & Fabio Pammolli, 2009. "I farmaci ospedalieri tra Europa, Stato, Regioni e Cittadini," Working Papers CERM 01-2009, Competitività, Regole, Mercati (CERM).
    8. Massimo Riccaboni & Fabio Pammolli & Sergey V. Buldyrev & Linda Ponta & H. Eugene Stanley, 2009. "The Size Variance Relationship of Business Firm Growth Rates," DISA Working Papers 0901, Department of Computer and Management Sciences, University of Trento, Italy, revised 11 Jun 2009.
    9. Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," The Quarterly Journal of Economics, Oxford University Press, vol. 119(3), pages 1049-1090.
    10. Carol Corrado & John Haltiwanger & Daniel Sichel, 2005. "Measuring Capital in the New Economy," NBER Books, National Bureau of Economic Research, Inc, number corr05-1, March.
    11. Stefano Capri & Rossella Levaggi, 2010. "Shifting the risk in pricing and reimbursement schemes. A new model of risk-sharing agreements for innovative drugs," LIUC Papers in Economics 234, Cattaneo University (LIUC).
    12. Margaret K. Kyle, 2007. "Pharmaceutical Price Controls and Entry Strategies," The Review of Economics and Statistics, MIT Press, vol. 89(1), pages 88-99, February.
    13. Towse, A. & Garrison, L. & Puig-Peiro, R., 2012. "The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?," Occasional Papers 000167, Office of Health Economics.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Massimo Riccaboni & Stefano Schiavo, 2009. "The Structure and Growth of International Trade," Documents de Travail de l'OFCE 2009-24, Observatoire Francais des Conjonctures Economiques (OFCE).
    2. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
    3. Massimo Riccaboni & Stefano Schiavo, 2009. "The Structure and Growth of Weighted Networks," Papers 0908.0348, arXiv.org, revised Dec 2009.
    4. Misako Takayasu & Hayafumi Watanabe & Hideki Takayasu, 2013. "Generalised central limit theorems for growth rate distribution of complex systems," Papers 1301.2728, arXiv.org, revised Jan 2014.
    5. Jakub Growiec & Fabio Pammolli & Massimo Riccaboni, 2020. "Innovation and Corporate Dynamics: A Theoretical Framework," Central European Journal of Economic Modelling and Econometrics, Central European Journal of Economic Modelling and Econometrics, vol. 12(1), pages 1-45, March.
    6. Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016. "Late-stage pharmaceutical R&D and pricing policies under two-stage regulation," Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
    7. Xie, Wen-Jie & Gu, Gao-Feng & Zhou, Wei-Xing, 2010. "On the growth of primary industry and population of China’s counties," Physica A: Statistical Mechanics and its Applications, Elsevier, vol. 389(18), pages 3876-3882.
    8. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2017. "The Dynamics of Pharmaceutical Regulation and R&D Investments," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 19(1), pages 121-141, February.
    9. Michael Kremer & Christopher M. Snyder, 2018. "Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global Demand for HIV Pharmaceuticals," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 235-273, August.
    10. Pierre Dubois & Morten Sæthre, 2020. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," Econometrica, Econometric Society, vol. 88(6), pages 2503-2545, November.
    11. Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016. "Patents and the Global Diffusion of New Drugs," American Economic Review, American Economic Association, vol. 106(1), pages 136-164, January.
    12. Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2016. "Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry," RAND Journal of Economics, RAND Corporation, vol. 47(4), pages 857-890, November.
    13. Fiona M. Scott Morton & Ariel Dora Stern & Scott Stern, 2018. "The Impact of the Entry of Biosimilars: Evidence from Europe," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 173-210, August.
    14. ARATA Yoshiyuki, 2014. "Firm Growth and Laplace Distribution: The importance of large jumps," Discussion papers 14033, Research Institute of Economy, Trade and Industry (RIETI).
    15. Margaret K. Kyle, 2018. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 211-234, August.
    16. Abdulkadir Civan & Michael Maloney, 2017. "Launch Decisions of Pharmaceutical Companies," Journal of Economics and Financial Analysis, Tripal Publishing House, vol. 1(1), pages 35-58.
    17. Stephan Eger & Jörg Mahlich, 2014. "Pharmaceutical regulation in Europe and its impact on corporate R&D," Health Economics Review, Springer, vol. 4(1), pages 1-9, December.
    18. Williams, Michael A. & Baek, Grace & Li, Yiyang & Park, Leslie Y. & Zhao, Wei, 2017. "Global evidence on the distribution of GDP growth rates," Physica A: Statistical Mechanics and its Applications, Elsevier, vol. 468(C), pages 750-758.
    19. Magazzini Laura & Fabio Pammolli, 2013. "R&D, Within and Between Patent Competition in the Pharmaceutical Industry," Working Papers 3/2013, IMT Institute for Advanced Studies Lucca, revised Jul 2013.
    20. Bee, Marco & Riccaboni, Massimo & Schiavo, Stefano, 2017. "Where Gibrat meets Zipf: Scale and scope of French firms," Physica A: Statistical Mechanics and its Applications, Elsevier, vol. 481(C), pages 265-275.

    More about this item

    Keywords

    farmaci oncologici; sanità; sostenibilità;
    All these keywords.

    JEL classification:

    • D40 - Microeconomics - - Market Structure, Pricing, and Design - - - General
    • H50 - Public Economics - - National Government Expenditures and Related Policies - - - General
    • H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health
    • H70 - Public Economics - - State and Local Government; Intergovernmental Relations - - - General
    • H75 - Public Economics - - State and Local Government; Intergovernmental Relations - - - State and Local Government: Health, Education, and Welfare
    • H77 - Public Economics - - State and Local Government; Intergovernmental Relations - - - Intergovernmental Relations; Federalism
    • I0 - Health, Education, and Welfare - - General
    • I10 - Health, Education, and Welfare - - Health - - - General
    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ern:wpaper:02-2012. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Guido Bora`). General contact details of provider: https://edirc.repec.org/data/cermmit.html .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.